Date: 2012-03-20
Type of information: Licensing agreement
Compound: novel adenosine A2A antagonist
Company: Shire (UK-USA) Heptares (UK)
Therapeutic area: CNS diseases
Type agreement: licensing
development
commercialisation
Action mechanism: adenosine A2A antagonist- Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain. Inhibition of the A2A receptor is a validated mechanism in the treatment of CNS disorders.
Disease: CNS diseases
Details: Heptares Therapeutics, a GPCR drug discovery company, announces that an operating company of Shire has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development. Under the terms of the agreement Heptares grants Shire an exclusive licence to worldwide development and commercial rights to A2A antagonists discovered by Heptares. Last May Heptares and Pharmaceuticals have concluded an exclusive option agreement for this novel adenosine A2A antagonist.
Financial terms: Heptares receives upfront option grant and exercise payments and is also eligible to receive future development and commercial milestone payments up to US$190 million plus royalties on product sales. Further terms of the agreement are not being disclosed.
Latest news:
